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S U M M A R Y
Objectives: A multicenter, hospital-wide, clinical and epidemiological study was conducted to assess the
effectiveness of the mass inﬂuenza vaccination program during the 2009 H1N1 inﬂuenza pandemic, and
the impact of the prioritization strategy among people at different levels of risk.
Methods and results: Among the 34 359 medically attended patients who displayed an inﬂuenza-like
illness and had a rapid inﬂuenza diagnostic test (RIDT) at one of the three participating hospitals, 21.0%
tested positive for inﬂuenza A. The highest daily number of RIDT-positive cases in each hospital ranged
from 33 to 56. A well-ﬁtted multiple linear regression time-series model (R2 = 0.89) showed that the
establishment of special community ﬂu clinics averted an average of nine cases daily (p = 0.005), and an
increment of 10% in daily mean level of population immunity against pH1N1 through vaccination
prevented ﬁve cases daily (p < 0.001). Moreover, the regression model predicted ﬁve-fold or more RIDT-
positive cases if the mass inﬂuenza vaccination program had not been implemented, and 39.1% more
RIDT-positive cases if older adults had been prioritized for vaccination above school-aged children.
Conclusions: Mass inﬂuenza vaccination was an effective control measure, and school-aged children
should be assigned a higher priority for vaccination than older adults during an inﬂuenza pandemic.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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The pandemic H1N1 2009 inﬂuenza virus (pH1N1) emerged in
Mexico and the USA in April 2009, and spread worldwide within a* Corresponding author. Tel.: +886 2 2312 3456 ext. 65054;
fax: +886 2 2397 1412.
E-mail address: yeechunchen@gmail.com (Y.-C. Chen).
1 Additional members of The Taiwan Infectious Diseases Study Network
(TIDSNet) for the pandemic H1N1 2009 inﬂuenza vaccination who contributed
data are listed at the end of this article.
http://dx.doi.org/10.1016/j.ijid.2014.02.016
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).few months.1 Both non-pharmaceutical control measures (including
border control, use of face masks, social distancing, and school
closures) and pharmaceutical control measures (such as vaccination
and antiviral drugs) were applied to mitigate the impact of
the pandemic. In particular, the development of an effective
vaccination strategy was considered as the most important
pharmaceutical measure.2 Thus, numerous countries launched
unprecedented mass inﬂuenza vaccination programs to timely
immunize as many people as possible. Although previous studies
have demonstrated the effectiveness of inﬂuenza vaccination for
high-risk groups of people,3–5 empirical evidence on the effective-ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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non-high-risk populations during the pandemic is still very limited.
Yet, given the time constraints for developing an effective
pandemic inﬂuenza vaccine and the required production capacity,
it seems unlikely that sufﬁcient quantities of a newly developed
vaccine will be available to protect the entire population during the
early stage of the pandemic. The limited stocks of vaccine should
therefore be prioritized among the different risk groups of a
population to maximize its overall effectiveness. As such, the US
Centers for Disease Control and Prevention recommended that
seasonal inﬂuenza vaccines be given to children aged 6 months to 5
years and adults aged 50 years or older up to the inﬂuenza season
of 2008–2009.6 For the 2009 H1N1 inﬂuenza pandemic, initial
target groups for vaccination efforts included pregnant women,
people who live with or provide care for infants aged 6 months or
less, health care and emergency medical services personnel,
children and young adults aged 6 months to 24 years, and people
aged 25–64 years who had medical conditions placing them at
increased risk of inﬂuenza-related complications.7 The guiding
principle of these recommendations was to vaccinate as many
people as possible within a short time-period. The Taiwanese
government acted on these recommendations. Accordingly, adults
aged 65 years or older (about 11% of the general population in
Taiwan) were not prioritized for the pH1N1 inﬂuenza vaccination.8
On the other hand, since school-aged children have relatively low
morbidity and mortality, whether they should be assigned the
highest priority for vaccination was considered debatable.9
Empirical data at the individual and population levels to assess
the impact of vaccination, and to compare the overall effectiveness
among different vaccination strategies against pH1N1 infection,
were found to be limited. We previously performed a retrospective
search of various data sources in Taiwan which yielded the recorded
daily numbers of positive rapid inﬂuenza diagnostic tests (RIDTs) at
hospitals, the nationwide immunization rates, and the reported
immunogenicity of the pH1N1 vaccine from local epidemiological
studies. With these data, we sought to analyze the daily numbers of
positive RIDTs at selected hospitals, as a proxy variable for hospital-
wide surveillance of inﬂuenza activity over time, with inclusion of
other available variables to assess the overall effectiveness of the
ﬁrst mass vaccination campaign in Taiwan. Since hospital-level data
are almost always available, the results of this study should be
beneﬁcial to the control of future episodes.Table 1
The 2009 H1N1 inﬂuenza pandemic timeline and implementation of the National
Date Action/event
April 28 Central Epidemic Command Center establis
April 29 Border control and onboard quarantine insp
May 20 The ﬁrst imported case conﬁrmed
Late May Release of surgical masks from national sto
June 11 Announcement of the inﬂuenza pandemic b
August 15 Provision of free rapid inﬂuenza diagnostic
August 18 Establishment of the school/class suspensio
September 5 Establishment of community ﬂu clinics
November 1 Beginning of the mass vaccination campaig
November 2 Vaccination for health care workers
November 9 Vaccination for infants aged 6–11 months
November 16 Vaccination for children aged 1–6 years, pr
November 23 Vaccination for junior high school students
November 30 Vaccination for senior high school students
December 1 Vaccination for adults aged 19–24 years an
December 7 Vaccination for people with speciﬁc chroni
December 12 Vaccination offered to all citizens
WHO, World Health Organization.2. Subjects and methods
2.1. Ethical considerations
This study was approved by the institutional review boards of
the three participating hospitals.
2.2. Study populations and design
Three teaching hospitals, National Taiwan University Hospital
(hospital N), Chung-Shan Medical University Hospital (hospital M),
and Kaohsiung Medical University Hospital (hospital S), located in
northern, central, and southern Taiwan, respectively, participated
in this multicenter epidemiological study. As listed in Table 1 and
in the Supplementary Material Table S1, all three of these
hospitals provided both primary and tertiary medical care to the
general population and established special ﬂu clinics during the
2009 ﬂu pandemic, where the RIDTs (QuickVue; Quidel, CA, USA)
using nasopharyngeal swabs were made available to inpatients,
outpatients, and health care workers with an inﬂuenza-like illness
(ILI). A case patient was deﬁned as a subject who had a positive
result for inﬂuenza A on the RIDT. To estimate the disease burden
and surge capacity against pH1N1 inﬂuenza, each study hospital
collected the RIDT results daily as hospital-wide surveillance of
inﬂuenza activity from August 15, 2009 to March 31, 2010. The
daily numbers of case patients as a proxy variable for pH1N1
activity at the hospital level were analyzed in this study.
2.3. Non-pharmaceutical interventions
From the time that the pH1N1 outbreak in Mexico was ofﬁcially
recognized, the Taiwan government implemented several pre-
deﬁned intensive control measures to contain pH1N1 infections in
a timely manner, in accordance with the National Inﬂuenza
Pandemic Control Plan (Table 1). These measures included border
control and quarantine, distribution of surgical masks, increased
disease surveillance activities, and the formulation of policies on
school and class suspensions.10
2.4. Pharmaceutical interventions
The number of patients seeking medical care for ILI from the
emergency services and in outpatient clinics increased rapidly after
week 33 of 2009.11Following the declaration of pandemic phase 6 by Pandemic Inﬂuenza Control Plan in Taiwan
hed to coordinate the use of resources and implement control measures
ection
ckpile
y WHO
 tests and antivirals
n policy
n by priority groups
egnant women, elementary school students, and people with severe illness
d the hospitalized high-risk group
c diseases
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mitigation stage on August 15, 2009, free RIDTs were delivered to
various medical institutions in Taiwan for people with ILI (Table 1).11
The antiviral agent, oseltamivir, was provided free of charge to
patients with a positive RIDT result, patients clinically diagnosed
with complicated inﬂuenza, and people with conditions associated
with an increased risk of complications from inﬂuenza. To enhance
accessibility to these medical services, the Taipei Department of
Health launched 212 community ﬂu clinics starting September 5,
2009. These included 34 special ﬂu outpatient clinics in the hospitals
and 178 volunteer general practitioners from the clinics.
The Department of Health in Taiwan then began a nationwide
pH1N1 vaccination program on November 1, 2009. A total of 15
million free vaccine doses were prepared for the entire population.
According to the predetermined priority for vaccination, health
care workers, preschool children, and school-aged children were
among the top priorities for vaccination (Table 1).12 An MF59-
adjuvant inactivated H1N1 vaccine (Novartis Vaccines and
Diagnostics, Sovicille, Italy) was used in children aged 6 months,
and a newly licensed inactivated H1N1 vaccine without adjuvant
(Adimmune Corporation, Taichung, Taiwan) was used in subjects
aged 1 year. Both vaccines were prepared against A/California/7/
2009 (H1N1)-like strains. A total of 5.67 million doses were
administered from November 1, 2009 to March 31, 2010.12 As a
result, 22.4% of the population received at least one dose of the
H1N1 vaccine, including 29.3% of persons aged 6 months to 6 years,
71.7% of persons aged 7–18 years, and 11.3% of persons aged 19
years. The age-speciﬁc immunogenicity of one of the pH1N1
vaccines (Adimmune Corporation, Taichung, Taiwan) was reported
from two local clinical trials.13,14 Because an age-based priority
plan was implemented in the nationwide vaccination program8
and the immunization efﬁcacy of the vaccination is affected by age,
we divided subjects into four age groups in our analysis: <6 years,
6–18 years, 19–64 years, and 65 years.
2.5. Statistical analysis
Data preparation and the statistical analysis were performed
using the freely available statistical software R, version 2.11.1 (The
R Foundation for Statistical Computing, Vienna, Austria). In the
statistical testing, a two-sided p-value of 0.05 was considered
statistically signiﬁcant. After descriptive analyses were done, a
time-series analysis was conducted using multiple linear regres-
sion models to estimate the effects of predicting factors on theTable 2
Characteristics of the subjects who underwent rapid inﬂuenza diagnostic testing (RIDT
Characteristic Total 
Whole population
Immunization coverage rate33 22% 
Estimated seroconversion rate after vaccination13,14
Hospital N (northern Taiwan)
RIDTs performed, n 13 799 
Positive RIDTs, n (%) 3463 (25.1) 
Hospital M (middle Taiwan)
RIDTs performed, n 12 190 
Positive RIDTs, n (%) 2196 (18.0) 
Hospital S (southern Taiwan)
RIDTs performed, n 8370 
Positive RIDTs, n (%) 1547 (18.5) 
Total
RIDTs performed, n 34 359 
Positive RIDTs, n (%) 7126 (21.0) daily number of case patients in the three separate hospitals during
the pandemic (see Supplementary Material, Text S1).
In regression analysis of the daily time-series data, the impacts
of age, gender, establishment of community ﬂu clinics, and average
daily immunity against inﬂuenza (derived from vaccination among
health care workers and the whole population) were investigated
with the guide of substantive knowledge of the pandemic. As
discussed in the statistical literature,15,16 the following three
statistical issues were also considered and handled appropriately:
autocorrelation, time lags, and oscillation. The autocorrelation
between repeated measurements of the response variable was
controlled explicitly by adding the past responses into the
regression model as covariates. To explore the time-lag effects
of past responses and interventions (including the time lag from
policy to implementation of a speciﬁc intervention and the time lag
between intervention and outcome), all the potential time lags for
the past responses and interventions were considered and then
determined during the stepwise variable selection procedure.
Then, as usual, the oscillation was modeled by specifying several
pairs of sine and cosine functions with chosen frequencies to
account for consistent cyclic or periodic variations over time in the
multiple linear regression time-series model.15,16 The multiple
competitive frequencies, amplitudes, and phases of oscillation
were also determined by the stepwise variable selection proce-
dure.
To accommodate the special features of infectious disease data,
two novel covariates were derived in our time-series regression
analysis. First, we constructed a binary variable to assign ‘1’ for the
days since the 7th day after the establishment of a special ‘ﬂu clinic’
until its closure, ‘0’ otherwise. Second, we estimated the daily
mean level of population immunity, H(t), using the following
formula: H(t) = (number of subjects having immunity against
pH1N1 at day t)/(total number of subjects), where the numerator,
the number of subjects having immunity on day t, was estimated
by a Monte Carlo simulation (see Supplementary Material, Text
S1). These two covariates helped us examine the effects of the
establishment of community ﬂu clinic and government age-
speciﬁc vaccination policy on the control of the pH1N1 inﬂuenza in
our time-series regression analysis.
The goal of time-series regression analysis was to ﬁnd one or a
few parsimonious regression models that ﬁtted the observed time-
series data well for effect estimation and/or outcome prediction. To
ensure the quality of the analysis, basic model-ﬁtting techniques
for (1) variable selection, (2) goodness-of-ﬁt (GOF) assessment,
and (3) regression diagnostics were used in our time-series) during the ﬂu pandemic with age group
Age group
6 months to
5 years
6–18 years 19–64 years 65 years
29% 72% 11% 11%
78% 82% 95% 72%
3407 3999 5354 1039
601 (17.6) 1832 (45.8) 977 (18.2) 53 (5.1)
2585 3480 5148 977
196 (7.6) 1283 (36.9) 692 (13.4) 25 (2.6)
2097 2332 3376 565
263 (12.5) 794 (34.0) 468 (13.9) 22 (3.9)
8089 9811 13 878 2581
1060 (13.1) 3909 (39.8) 2137 (15.4) 100 (3.9)
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procedure (with iterations between the forward and backward
steps) was applied to obtain the best candidate ﬁnal regression
model. The signiﬁcance levels for entry (SLE) and for stay (SLS)
were set to 0.15 for conservativeness. Then, with the aid of
substantive knowledge, the best candidate ﬁnal regression model
was identiﬁed manually by dropping the covariates with a p-value
>0.05 one at a time until all regression coefﬁcients were
signiﬁcantly different from 0. Generalized additive models
(GAM) were used to detect nonlinear effects of continuous
covariates, and potential interactive effects between some
covariates were considered during the stepwise variable selection
procedure. The coefﬁcient of determination (R2) was examined to
assess the GOF of the ﬁtted linear regression model. Technically,
the R2 statistic (0  R2  1) equals the square of the Pearson
correlation between the observed and predicted response values
and it indicates how much of the response variability is explained
by the covariates included in the linear regression model. The
statistical tools for regression diagnostics such as residual analysis,
identiﬁcation of inﬂuential cases, and detection of multicollinear-
ity were applied to discover model or data problems.
3. Results
3.1. Study population
A total of 34 359 inpatients and outpatients had an RIDT during
the study period and 21% tested positive for inﬂuenza A (Table 2). In
particular, school-aged children had the highest positive RIDT rateTable 3
Multiple linear regression time-series analysis of the factors predicting the daily number
hospitalsa
Covariate 
Hospital N
Intercept 
Average immunity of health care workers 
Establishment of community ﬂu clinics 5 days before 
Average population immunityc
Cosine oscillation with frequency of 7 days 
Number of positive cases 2 days before 
Number of positive cases 3 days before 
Number of positive cases 5 days before 
Number of positive cases 6 days before 
Number of positive cases 7 days before 
Interaction between average population immunity and establishment
of community ﬂu clinics 5 days before
Hospital M
Intercept 
Average population immunityc
Number of positive cases 1 day before 
Number of positive cases 4 days before 
Number of positive cases 7 days before 
Hospital S
Intercept 
Mean age (years) 
Establishment of ﬂu clinics 7 days before 
Average population immunityc
Cosine oscillation with frequency of 2 days 
Cosine oscillation with frequency of 7 days 
Cosine oscillation with frequency of 30 days 
Number of positive cases 1 day before 
Number of positive cases 7 days before 
Interaction between average population immunity and establishment
of community ﬂu clinics 7 days before
a Only the covariates with statistically signiﬁcantly non-zero regression coefﬁcients 
b Goodness-of-ﬁt assessment: multiple R2 = 0.89 for hospital N, 0.73 for hospital M, 
c The daily mean level of population immunity against pH1N1 was estimated using th
day t)/(total number of subjects), where the number of subjects having immunity aga
Supplementary Material, Text S1).(39.8%), which was about 10-fold higher than the average rate in
older adults (3.9%) (Table 2; Supplementary Material Figure S1).
3.2. Time trend analysis
Figure 1 shows the daily number of positive cases at each
hospital. Based on the RIDT results, the highest daily number of
positive cases in each hospital ranged from 33 to 56. Two distinct
waves occurred in late August and late October, respectively, which
were consistently observed in the epidemic curves of the three
hospitals. The ﬁrst and second peaks appeared slightly earlier in
hospital N than in the two other hospitals (Figure 1). After December
2009, the number of positive cases decreased gradually in all three
hospitals. Yet, the variation in the three epidemic curves revealed a
spatial diffusion pattern of the pandemic across Taiwan.17
3.3. Impact of pharmaceutical interventions
The daily RIDT data from the three hospitals were analyzed
separately due to the potential differences between hospitals and
located areas. A multiple linear regression time-series model was
ﬁtted to the daily RIDT data of each participating hospital to
estimate the effects of predicting factors on the daily number of
positive cases, thereby assessing the impacts of implemented
pharmaceutical interventions. As listed in Table 3, after adjusting
for the effects of the other covariates (or while the values of the
other covariates were held ﬁxed), the establishment of community
ﬂu clinics averted a mean number of 8.7 daily cases (p = 0.005) and
every 10% increment in the daily mean level of population
immunity against pH1N1 through vaccination resulted in a of cases with positive rapid inﬂuenza diagnostic tests (RIDTs) at the three teaching
Estimateb Standard
error
p-Value
20.03 2.49 <0.01
8.12 1.42 0.01
8.70 2.16 <0.01
51.34 9.07 <0.01
1.93 0.52 <0.01
0.34 0.06 <0.01
0.29 0.07 <0.01
0.15 0.07 0.02
0.13 0.06 0.04
0.22 0.06 <0.01
29.62 7.38 <0.01
1.46 0.64 0.02
6.61 3.25 0.04
0.45 0.06 <0.01
0.23 0.06 <0.01
0.18 0.06 0.02
24.16 2.72 <0.01
0.15 0.07 0.05
12.04 1.28 <0.01
75.56 7.97 <0.01
0.60 0.29 0.04
0.88 0.42 0.04
1.02 0.42 0.02
0.17 0.07 0.01
0.19 0.05 <0.01
49.89 6.79 <0.01
are listed in this table.
and 0.84 for hospital S.
e following formula: H(t) = (number of subjects having immunity against pH1N1 at
inst pH1N1 at day t was estimated by Monte Carlo simulation (described in the
Figure 1. Daily number of medically attended inﬂuenza-like illness (ILI) cases laboratory conﬁrmed as inﬂuenza A at the three teaching hospitals from August 15, 2009 to
March 31, 2010. (a) Establishment of community ﬂu clinics. (b) Vaccination for health care workers. (c) Vaccination for pre-school children. (d) Vaccination for school
children. (e) Vaccination for adults aged 19–24 years. (f) Vaccination for all citizens including the elderly. (g) Community ﬂu clinics closed.
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Figure 2. Simulated model of the daily number of cases with positive RIDTs at hospital N if vaccination was performed earlier among the elderly people than school-aged
children. (a) Establishment of community ﬂu clinics. (b) Vaccination for health care workers. (c) Vaccination for pre-school children. (d) Vaccination for the elderly. (e)
Vaccination for school children. (f) Vaccination for adults aged 19–24 years. (g) Community ﬂu clinics closed.
U.-I. Wu et al. / International Journal of Infectious Diseases 23 (2014) 82–89 87reduction of a mean number of 5.1 daily cases beginning on
November 1, 2009 (p < 0.001) in hospital N. The GOF measure
R2 = 0.89 indicated that this linear regression model ﬁtted the daily
RIDT data of hospital N well. Similar results were detected in the
other two participating hospitals (Table 3).
3.4. What-if analysis
3.4.1. Scenario 1: What if the mass vaccination was not implemented?
While the values of all the other covariates shown in Table 3
were held ﬁxed, a ﬁve-fold or greater increase in the mean number
of daily cases would have occurred at hospital N during the study
period had mass vaccination not been implemented.
3.4.2. Scenario 2: What if the elderly people were prioritized above
school-aged children in mass vaccination?
While the values of all the other covariates shown in Table 3
were held ﬁxed, if the elderly people were prioritized above
school-aged children in mass vaccination, 39.1% more positive
cases would have occurred between December 1, 2009, and
January 7, 2010 in hospital N as compared to the implemented
vaccination policy (Figure 2).
4. Discussion
In this multicenter, hospital-wide, clinical and epidemiological
study, we examined the effectiveness of the mass pH1N1
vaccination, and the integrated measures of providing RIDT and
antiviral therapy against inﬂuenza A between August 15, 2009 and
March 31, 2010 in Taiwan. The daily number of laboratory
conﬁrmed inﬂuenza A infections, rather than non-speciﬁc out-
comes (such as ILI or pneumonia), was analyzed as a proxy for
pH1N1 inﬂuenza activity. In particular, the age-based vaccination
coverage rate12 and the immunogenicity of the pH1N1 vaccine13,14
were incorporated into our analysis. The results were consistent
with the reported epidemic statistics from the national surveil-
lance system (Supplementary Material Figure S2).18
Similar to the conclusions of previous studies,19–23 this study
found that mass inﬂuenza vaccination was effective for pandemic
inﬂuenza control and it was a more effective pharmaceutical
intervention than antiviral therapy. In fact, although the vaccina-
tion coverage rate was only about 22.4% in Taiwan, a substantial
proportion of potential inﬂuenza cases was prevented through the
mass inﬂuenza vaccination. The baseline seroprotective rate of
Taiwanese people immediately before the initiation of the massinﬂuenza vaccination program was relatively low – only 4.8% in
adults and 7.2% in children13,14 (Table 1). However, even with an
estimated basic reproduction number of 1.5 (median) for pH1N1
infection,24 the overall attack rate was only 20.6% in unvaccinated
people.25 Hence, the sharp decline in infected cases after the
implementation of mass inﬂuenza vaccination cannot be explained
solely by population immunity from natural infection and the
exhaustion of susceptible hosts. Based on the notion that the
pH1N1 virus possesses greater viral replication competence than
seasonal inﬂuenza A virus,26,27 and the typical peak inﬂuenza
season in Taiwan arises between December and February18
(Supplementary Material Figure S2), the pandemic would have
lasted much longer without the mass inﬂuenza vaccination
campaign. Recent reports have also shown that additional
pandemic waves, as seen in previous inﬂuenza pandemics
(1918, 1957, and 1968), could be mitigated by mass vaccina-
tion.28,29
Given the urgent huge demand, the limited vaccine capacity,
and the timeliness of vaccine supply, vaccine prioritization among
people at different levels of risk was crucial to the success of the
mass inﬂuenza vaccination program during the pandemic. In
setting priorities for a mass vaccination campaign, two risk groups
competing for priority are: (1) people at high risk of severe health
consequences, and (2) those most susceptible and more likely to
spread the infection. While the pH1N1 virus was predominant in
children and younger adults,30,31 the case-fatality rate was the
lowest in people younger than 18 years and the highest among
older adults.32 On the other hand, the age distribution of
hospitalized patients during the pandemic differed from that of
the usual inﬂuenza seasons – more hospitalizations among
younger age groups and fewer among adults aged 65 years and
older.32 It should be considered that school-aged children could
transmit inﬂuenza in the community and their parents and
teachers could serve as bridges of infection to the other people in
the population. In addition, granting school-aged children a high
priority for immunization could reach a large vaccination coverage
in a population within a short time-period due to the high
efﬁciency of the school-based delivery of vaccines and implemen-
tation of vaccination.21 Consistent with earlier studies,23,33 we
found that the preferential vaccination of school-aged children had
a larger positive impact than prioritizing older adults for
immunization on the control of the inﬂuenza pandemic. Owing
to a higher susceptibility of children to inﬂuenza compared to
adults, and schools are known to play a signiﬁcant role in spreading
the virus,19,34,35 it is conceivable that school-aged children
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despite broad vaccine coverage. We postulate that the unavail-
ability of a mass vaccination campaign would have resulted in an
even higher rate of inﬂuenza among school-aged children
according to our analysis.
In addition to vaccination, the establishment of community ﬂu
clinics was an effective control measure to mitigate the inﬂuenza
pandemic in several respects. First, it provided infected patients
with easy and quick access to both free RIDTs and antivirals,
thereby shortening the period of infectiousness. It has been shown
that the time period from the onset of illness to the start of antiviral
therapy was shortened after the community ﬂu clinics were
established.36 Second, it prevented patients with ILI from visiting
hospitals directly, thus reducing the risks of cross-transmission
among both patients and health care workers within hospitals. A
recent analysis illustrated that the incidence of pH1N1 infections
among health care workers declined markedly after the imple-
mentation of the community ﬂu clinics.37
In this study, the daily RIDT data from the three participating
hospitals, located in northern, central, and southern Taiwan,
respectively, were analyzed separately because the patterns of the
epidemic curves derived from these three hospitals differed
slightly according to the spatio-temporal diffusion pattern of the
inﬂuenza pandemic across the country.38 The ﬁrst imported case of
pH1N1 was found in northern Taiwan where the population
density is the highest, consequently the rate of infection was
higher than those of the central and southern areas. In addition,
regional differences in population density, climate, clinical
practice, and medical care-seeking behavior might in part account
for the differences. Nevertheless, the main ﬁndings from each
hospital were consistent and reproducible.
A unique aspect of this empirical study was the time-series
regression analysis of the daily RIDT data for estimating the effects
of various control measures and predicting future responses. As
compared to other analysis techniques, regression analysis is
transparent, straightforward, and easy to perform in practice. In
this study, the information about the infection rate, the immuno-
genicity of pH1N1 vaccine, and the proportion of vaccine uptake in
each age group were derived from a high quality database and then
included in our regression analysis. The identiﬁed oscillations
could be a consequence of dynamic interactions between climatic,
environmental, social, and behavioral factors.39
With the limited hospital-based epidemic data, we did not
adopt the usual infectious disease modeling approach, such as
ﬁtting a stochastic susceptible–exposed–infectious–recovered
(SEIR) model for analyzing the daily RIDT data, to avoid the
unveriﬁable assumptions and the complexity in mathematical or
statistical modeling.40 In particular, it was difﬁcult to specify
correctly the size of the susceptible population in a hospital-based
open territory and to incorporate too many risk factors and control
measures into a stochastic epidemic model.41 Some previous
studies had attempted to evaluate optimal vaccination strategies
for pH1N1 with mathematical epidemic models,42–44 but mathe-
matical assumptions had limitations in application. A few case–
control studies also assessed the effectiveness of pH1N1 vac-
cine,45–48 but they failed to consider the population effects of
vaccination, such as herd immunity and the time-varying coverage
rate in an age-based vaccination program.
Nevertheless, this study had some limitations. First, our
analysis focused on the effects of mass inﬂuenza vaccination
and community ﬂu clinics on the occurrence and transmission of
inﬂuenza, but we did not consider the resultant morbidities,
mortalities, or economic costs. Second, we were unable to identify
some subjects potentially at increased risk of severe outcomes in
our database. Thus, we could not determine the impact of the
vaccination-prioritizing strategy on those with underlying chronicdiseases or pregnant women. Third, although the multiple linear
regression time-series model ﬁtted the daily RIDT data well as an
alternative approach to evaluating the effectiveness of control
measures, the statistical regression model might only provide an
approximation to each covariate’s true effect. Fourth, the effects of
non-pharmaceutical control measures, including border control,
use of face masks, social distancing, and school closures, were not
considered in this study because they were implemented before
the RIDT was widely adopted as a diagnostic tool.49 Fifth, as
compared to community-based seroepidemiological studies, the
number of positive RIDTs as a proxy for inﬂuenza activity would
probably underestimate the incidence of this disease. Also, the
performance of RIDTs varies with the timing and method of
specimen collection, storage method, and participant’s age.50
Nevertheless, the epidemic curves derived from the daily numbers
of positive RIDTs were comparable to the RT-PCR and viral culture
data collected by the Taiwan Center for Disease Control in a
national surveillance of pH1N1 infection.51 Lastly, further sub-
typing of inﬂuenza A virus detected by the RIDTs was not
performed, but more than 95% of the inﬂuenza viruses circulating
in Taiwan during the pandemic were pH1N1.18,52
In summary, vaccination was an effective and important control
measure at both individual and population levels during the
inﬂuenza pandemic in Taiwan. Based on the results of our regression
analysis, school-aged children should be assigned a higher priority
for mass inﬂuenza vaccination than older adults. The results of this
study provided a framework for the development of optimal mass
vaccination strategies for future inﬂuenza pandemics.
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